Journey Medical Corporation (DERM) Financial Statements (2024 and earlier)

Company Profile

Business Address 9237 E VIA DE VENTURA BLVD., SUITE 105
SCOTTSDALE, AZ 85258
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27,43924,7498,23017,34932,00334,891
Cash and cash equivalents27,43924,7498,23017,34932,00334,891
Restricted cash and investments   8,750   
Receivables15,2227,98916,73727,61628,20828,533
Inventory, net of allowances, customer advances and progress billings10,20611,02412,16613,27814,15915,230
Inventory10,20611,02412,16613,27814,15915,230
Other undisclosed current assets3,5889241,7962,4773,309942
Total current assets:56,45544,68647,67960,72077,67979,596
Noncurrent Assets
Operating lease, right-of-use asset10112414616718922
Intangible assets, net (including goodwill)20,28721,10221,91626,12827,19728,424
Intangible assets, net (excluding goodwill)20,28721,10221,91626,12827,19728,424
Restricted cash and investments    8,750  
Other noncurrent assets6668895103
Total noncurrent assets:20,39421,23222,06835,13327,48128,549
TOTAL ASSETS:76,84965,91869,74795,853105,160108,145
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities38,49944,19055,10261,03355,95854,283
Interest and dividends payable125
Taxes payable22
Employee-related liabilities2,727
Accounts payable18,14928,16431,77343,65836,57033,626
Accrued liabilities20,35016,02623,32917,37519,38817,783
Debt   9,9429,9142,948 
Other liabilities1951,093603   
Due to related parties37041374
Other undisclosed current liabilities3,1743,2272,5465,5817,5136,420
Total current liabilities:41,86848,51068,19376,89866,83260,777
Noncurrent Liabilities
Long-term debt and lease obligation14,622  9,92919,82619,810
Long-term debt, excluding current maturities14,622  9,92919,82619,810
Liabilities, other than long-term debt 9345984108 
Operating lease, liability 9345984108 
Other undisclosed noncurrent liabilities   1,4901,4501,4121,374
Total noncurrent liabilities:14,631341,54911,46321,34621,184
Total liabilities:56,49948,54469,74288,36188,17881,961
Equity
Equity, attributable to parent, including:20,35017,37457,49216,98226,184
Additional paid in capital92,70387,58487,00486,12885,48284,042
Accumulated deficit(72,355)(70,212)(87,001)(78,638)(68,502)(57,860)
Other undisclosed equity, attributable to parent222222
Total equity:20,35017,37457,49216,98226,184
TOTAL LIABILITIES AND EQUITY:76,84965,91869,74795,853105,160108,145

Income Statement (P&L) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Revenues15,25734,53917,17212,21315,96616,116
Other income  19,260211484573
Cost of revenue(6,015)(6,429)(7,767)(6,449)(7,718)(7,221)
Gross profit:9,24228,1109,4055,7648,2488,895
Operating expenses(11,346)(10,865)(17,058)(15,325)(18,243)(18,387)
Operating income (loss):(2,104)17,245(7,653)(9,561)(9,995)(9,492)
Nonoperating income (expense)87(361)(710)(575)(634)(578)
Loss, foreign currency transaction, before tax(2)(101)(33)(47)(67)(22)
Interest and debt expense(24)(268)(756)(650)(617)(559)
Income (loss) from continuing operations before equity method investments, income taxes:(2,041)16,616(9,119)(10,786)(11,246)(10,629)
Other undisclosed income from continuing operations before income taxes24268756650617559
Income (loss) from continuing operations before income taxes:(2,017)16,884(8,363)(10,136)(10,629)(10,070)
Income tax expense (126)(95)  (13)(10)
Income (loss) from continuing operations:(2,143)16,789(8,363)(10,136)(10,642)(10,080)
Loss before gain (loss) on sale of properties:(10,080)
Net income (loss) available to common stockholders, diluted:(2,143)16,789(8,363)(10,136)(10,642)(10,080)

Comprehensive Income ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net income (loss):(2,143)16,789(8,363)(10,136)(10,642)(10,080)
Comprehensive income (loss), net of tax, attributable to parent:(2,143)16,789(8,363)(10,136)(10,642)(10,080)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: